|

Anti-CD123 LV redirected T cells (CART123) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Stephan Grupp MD PhD1

Indications

  • Acute Myeloid Leukemia (AML)1
  • Cancer1

Philadelphia, Pennsylvania1 trial

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Children's Hospital of Philadelphia

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.